Patents by Inventor Jeffery E. Cobb

Jeffery E. Cobb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11834411
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: December 5, 2023
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
    Publication number: 20220213036
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: Kenneth BATCHELOR, Jeffery E. COBB, Kristjan S. GUDMUNDSSON, Brad R. HENKE, Francis X. Tavares
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11261157
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 1, 2022
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20220034865
    Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
    Type: Application
    Filed: June 11, 2021
    Publication date: February 3, 2022
    Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
  • DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20200110069
    Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
    Type: Application
    Filed: October 14, 2019
    Publication date: April 9, 2020
    Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
  • Diagnostic methods, therapeutic agents and uses thereof
    Patent number: 10502729
    Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: December 10, 2019
    Assignee: Metabolon, Inc.
    Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
  • DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20180031541
    Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 1, 2018
    Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang